This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Pacemakers/ Defibrillators  • Cardiovascular System  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

The Need for Improved Risk Stratification

Anil Gehi, MD; Donald Haas, MD, MPH; Valentin Fuster, MD, PhD

JAMA. 2005;294:958-960.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Identification of patients at risk for sudden cardiac death (SCD) is a major challenge for the medical community. Although there have been advances in the area of risk stratification, it remains troubling that the majority of individuals who die of SCD are among a population that is not identified by current methods of risk stratification.¹ Nevertheless, several recent trials have attempted to identify groups of patients who may benefit from an implantable cardioverter-defibrillator (ICD).

Current guidelines recommend that survivors of cardiac arrest (occurring after the first 24 hours following myocardial infarction) receive an ICD for secondary prophylaxis of SCD.² However, identifying individuals for primary prophylaxis of SCD with an ICD has proven more difficult. Initial studies identified high-risk patients as those surviving myocardial infarction with significant left ventricular dysfunction and an abnormal electrophysiological study.^3-4 Most recently, the Sudden Cardiac . . . [Full Text of this Article]

Author Affiliations: The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Safety Issues Involving Medical Devices: Implications of Recent Implantable Cardioverter-Defibrillator Malfunctions
William H. Maisel
JAMA. 2005;294(8):955-958.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Selecting Patients for an Implantable Cardioverter-Defibrillator: Can the Genie Be Put Back Into the Bottle?
Mittal
J Am Coll Cardiol 2008;51:297-299.
FULL TEXT  

Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction
Rossi et al.
Heart 2007;93:1420-1425.
ABSTRACT | FULL TEXT  

Effect of Cardiac and Noncardiac Conditions on Survival After Defibrillator Implantation
Lee et al.
J Am Coll Cardiol 2007;49:2408-2415.
ABSTRACT | FULL TEXT  

The high cost of implantable defibrillators
Hlatky and Mark
Eur Heart J 2007;28:388-391.
ABSTRACT | FULL TEXT  

Microvolt T-Wave Alternans Identifies Patients With Ischemic Cardiomyopathy Who Benefit From Implantable Cardioverter-Defibrillator Therapy
Chow et al.
J Am Coll Cardiol 2007;49:50-58.
ABSTRACT | FULL TEXT  

The Frequency and Incremental Cost of Major Complications Among Medicare Beneficiaries Receiving Implantable Cardioverter-Defibrillators
Reynolds et al.
J Am Coll Cardiol 2006;47:2493-2497.
ABSTRACT | FULL TEXT  

Reply
Gehi and Gomes
J Am Coll Cardiol 2006;47:1736-1737.
FULL TEXT